Based on this rationale, we conducted a phase 2, randomized, placebo control trials to evaluate whether low or high daily doses of sulforaphane for four weeks stimulated Nrf2 target gene expression in patients with COPD. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.